Retatrutide is a new pharmaceutical in the fight against obesity. This novel drug, categorized as a dual GLP-1 and GIP receptor agonist, shows promising results in clinical trials. By activating these receptors, https://nicoleibpg801225.blogsidea.com/42636108/setmelanotide-a-promising-new-treatment-for-obesity